Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, Inc.’s share was trading at $11.09 as of April 20th. VIR’s trailing P/E was 5.92 according to Yahoo Finance.
Photo by National Cancer Institute on Unsplash
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. VIR is repositioning its business around Chronic Hepatitis Delta (HDV) and its masked T cell engager oncology platform, with HDV emerging as the primary value driver. Its lead program combines tobevibart, a neutralizing monoclonal antibody, with elebsiran, an siRNA partnered with Alnylam Pharmaceuticals.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Phase 2 SOLSTICE data showed a 77% Target Not Detected (TND) rate at Week 72 for the combination versus 53% for monotherapy, reinforcing the dual-mechanism approach. However, regulatory uncertainty remains around whether on-treatment TND is sufficient or if durability data post-treatment will be required, potentially delaying the expected 2027 BLA timeline. The Phase 3 ECLIPSE program is critical, with full topline data expected in Q1 2027; successful replication of efficacy would significantly de-risk the asset, while failure could compress valuation materially.
In oncology, Vir’s PRO-XTEN platform aims to reduce off-target toxicity through dual masking, though its clinical validity remains unproven. Early data from VIR-5500 shows promising PSA responses, but the key risk lies in translating these into RECIST-confirmed tumor responses. Without this correlation, the platform may be assigned minimal value. Competitive pressure in HDV is intensifying, particularly from Gilead Sciences’ bulevirtide and Mirum Pharmaceuticals’ brelovitug, both of which could challenge Vir’s positioning depending on durability outcomes.
Financially, Vir holds $781 million in cash with runway into late 2027 under stable conditions, though dilution risk persists ahead of key data. A recent partnership with Norgine provides limited relief. With a 65% internal probability of success versus a 55% market-implied level, the stock offers moderate upside, but remains highly sensitive to the binary Q1 2027 readout, where success could drive a sharp rerating while failure may push shares toward liquidation-adjusted levels.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted the strong commercial potential of Casgevy, favorable reimbursement progress, and a deep gene-editing pipeline supporting long-term upside. CRSP’s stock price has appreciated by approximately 40.81% since our coverage. BioEquity Watch shares a similar view but emphasizes on Vir Biotechnology’s HDV program and binary clinical outcomes driving valuation.
Vir Biotechnology, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held VIR at the end of the fourth quarter which was 25 in the previous quarter. While we acknowledge the risk and potential of VIR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VIR and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
